Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
8.88
-0.34 (-3.69%)
At close: Mar 28, 2025, 4:00 PM
9.45
+0.57 (6.42%)
After-hours: Mar 28, 2025, 6:06 PM EDT
Myriad Genetics Market Cap
Myriad Genetics has a market cap or net worth of $810.82 million as of March 28, 2025. Its market cap has decreased by -58.10% in one year.
Market Cap
810.82M
Enterprise Value
848.72M
1-Year Change
-58.10%
Ranking
Category
Stock Price
$8.88
Market Cap Chart
Since December 1, 1998, Myriad Genetics's market cap has increased from $102.30M to $810.82M, an increase of 692.59%. That is a compound annual growth rate of 8.18%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 28, 2025 | 810.80M | -35.04% |
| Dec 31, 2024 | 1.25B | -20.67% |
| Dec 29, 2023 | 1.57B | 33.81% |
| Dec 30, 2022 | 1.18B | -46.65% |
| Dec 31, 2021 | 2.20B | 48.19% |
| Dec 31, 2020 | 1.49B | -26.57% |
| Dec 31, 2019 | 2.03B | -6.80% |
| Dec 31, 2018 | 2.17B | -8.61% |
| Dec 29, 2017 | 2.38B | 108.51% |
| Dec 30, 2016 | 1.14B | -62.13% |
| Dec 31, 2015 | 3.01B | 21.14% |
| Dec 31, 2014 | 2.49B | 58.51% |
| Dec 31, 2013 | 1.57B | -29.30% |
| Dec 31, 2012 | 2.22B | 25.03% |
| Dec 30, 2011 | 1.77B | -15.91% |
| Dec 31, 2010 | 2.11B | -15.93% |
| Dec 31, 2009 | 2.51B | -18.54% |
| Dec 31, 2008 | 3.08B | 50.95% |
| Dec 31, 2007 | 2.04B | 64.00% |
| Dec 29, 2006 | 1.24B | 93.29% |
| Dec 30, 2005 | 643.90M | -6.71% |
| Dec 31, 2004 | 690.20M | 98.11% |
| Dec 31, 2003 | 348.40M | -0.17% |
| Dec 31, 2002 | 349.00M | -71.84% |
| Dec 31, 2001 | 1.24B | -34.15% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 738.61B |
| UnitedHealth Group | 472.03B |
| Johnson & Johnson | 394.52B |
| AbbVie | 363.15B |
| Novo Nordisk | 305.46B |
| AstraZeneca | 229.16B |
| Abbott Laboratories | 226.88B |
| Merck & Co. | 225.40B |